** Shares of  drugmaker Theravance Biopharma TBPH.O fall 31% to $13.51 premarket

** Co says its board is reviewing options, including possible sale, after it ended development of experimental treatment for neurogenic orthostatic hypotension

** Neurogenic orthostatic hypotension is a condition where blood pressure drops sharply when standing

**  Co says it will end development of ampreloxetine and cut operating costs by about 60%, including reducing its administrative staff

**  TBPH says restructuring will affect around half its workforce and save about $70 mln annually

**  Co says it ended 2025 with $326.5 mln in cash; expects ~$400 mln by end-Q1 2026

** Shares up ~99% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))